ARTICLE | Company News
Bayer, Onyx complete sorafenib submission
July 11, 2005 11:59 PM UTC
Bayer (FSE:BAYG; BAY) and ONXX completed submission of a rolling NDA for sorafenib ( BAY 43-9006) to treat advanced renal cell carcinoma (RCC). The companies hope to launch the small molecule inhibito...